| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0161-6420(00)00035-X |
| P698 | PubMed publication ID | 10811092 |
| P2093 | author name string | D Stevenson | |
| J Tauber | |||
| B L Reis | |||
| P2860 | cites work | Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease | Q33643546 |
| Histology of the lacrimal gland in keratoconjunctivitis sicca | Q33997341 | ||
| Prevalence of dry eye in Japanese eye centers | Q34369619 | ||
| A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada | Q34441489 | ||
| Cytokines and autoimmune disease | Q37433285 | ||
| Prevalence of dry eye among the elderly | Q39457390 | ||
| Diagnostic implications of tear protein profiles | Q41858527 | ||
| Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren's syndrome | Q43585293 | ||
| Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years | Q44997732 | ||
| Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops | Q69674155 | ||
| The autoimmune nature of aqueous tear deficiency | Q69734017 | ||
| An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis | Q71064375 | ||
| Endophthalmitis associated with microbial keratitis | Q71833017 | ||
| Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome | Q72418731 | ||
| Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome | Q72658445 | ||
| P433 | issue | 5 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 967-974 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group | |
| P478 | volume | 107 |
| Q47121635 | A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers |
| Q90615647 | A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain |
| Q36296284 | A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients |
| Q36908429 | A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. |
| Q92236581 | A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops |
| Q92442286 | Advances in dry eye disease treatment |
| Q38904119 | Advances in the use of prodrugs for drug delivery to the eye. |
| Q52820593 | Adverse Effect Profile of Topical Ocular Administration of Fingolimod for Treatment of Dry Eye Disease. |
| Q79317939 | Anti-inflammatory therapy of dry eye |
| Q48126820 | Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis. |
| Q37071969 | Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression |
| Q24200233 | Autologous serum eye drops for dry eye |
| Q24234791 | Autologous serum eye drops for dry eye syndrome |
| Q30235522 | Autologous serum eye drops for dry eye. |
| Q36639883 | Challenges and pitfalls in clinical trials of treatments for dry eye. |
| Q38148616 | Changing trends in the treatment of dry-eye disease |
| Q34600435 | Character of ocular surface mucins and their alteration in dry eye disease |
| Q46437932 | Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno |
| Q56864480 | Ciclosporin use in dry eye disease patients |
| Q37782084 | Clinical Review: Topical Ophthalmic Use of Cyclosporin A |
| Q46939840 | Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. |
| Q39151688 | Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature |
| Q89906657 | Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial |
| Q90403137 | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| Q37905546 | Cornea: Window to Ocular Immunology |
| Q36269034 | Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q37781669 | Current insights into ocular graft-versus-host disease |
| Q46857139 | Current treatment for dry eye syndrome |
| Q35572113 | Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study |
| Q45012706 | Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children |
| Q45041371 | Cyclosporine 2% eye drops preparation |
| Q35577456 | Cyclosporine A delivery to the eye: A pharmaceutical challenge |
| Q28828737 | Cyclosporine Amicellar delivery system for dry eyes |
| Q35570541 | Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence |
| Q33526896 | Data Monitoring Committees. |
| Q80347916 | Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007) |
| Q33274135 | Differential diagnoses of conjunctivitis for clinical allergist-immunologists |
| Q57171838 | Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics |
| Q35344219 | Dry eye after laser in-situ keratomileusis |
| Q34123349 | Dry eye disease |
| Q36799601 | Dry eye disease and microbial keratitis: is there a connection? |
| Q36916372 | Dry eye disease: an immune-mediated ocular surface disorder |
| Q34247350 | Dry eye in the elderly |
| Q42578739 | Dry eye syndrome |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q39384374 | Dry eye. An update on epidemiology, diagnosis, therapy and new concepts |
| Q26852044 | Dry eye: an inflammatory ocular disease |
| Q35790953 | Dry eye: diagnosis and current treatment strategies |
| Q34338027 | Effect of inflammation on lacrimal gland function. |
| Q51836466 | Effects of Aging in Dry Eye. |
| Q46025632 | Efficacy of a 2-month dietary supplementation with polyunsaturated fatty acids in dry eye induced by scopolamine in a rat model. |
| Q35581180 | Emerging drugs for ophthalmic diseases. |
| Q34371781 | Emerging treatment options for meibomian gland dysfunction |
| Q35805082 | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). |
| Q36929473 | Graft failure: II. Ocular surface complications |
| Q38090503 | Graft versus host disease: clinical evaluation, diagnosis and management |
| Q33861286 | HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease |
| Q34076208 | High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen |
| Q58598414 | Impact of Vehicle Physicochemical Properties on Modeling-Based Predictions of Cyclosporine Ophthalmic Emulsion Bioavailability and Tear Film Breakup Time |
| Q36393194 | Improvement in the signs and symptoms of dry eye disease with dobesilate eye drops |
| Q39878699 | In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants. |
| Q60047806 | Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests |
| Q53534950 | Keratitis in Dry Eye Disease and Topical Ciclosporin A. |
| Q38608475 | Lifitegrast for the treatment of dry eye disease in adults |
| Q33727906 | Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis. |
| Q80347919 | Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007) |
| Q34028408 | Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. |
| Q47442388 | Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. |
| Q35799409 | Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution |
| Q62398521 | Mucosal Immunity and Self-Tolerance in the Ocular Surface System |
| Q38058002 | New agents for treating dry eye syndrome. |
| Q79537020 | New insights into the diagnosis and treatment of dry eye |
| Q28238074 | Nocturnal lagophthalmos: an overview and classification |
| Q34730735 | Ocular allergy guidelines: a practical treatment algorithm |
| Q36068686 | Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. |
| Q81551290 | Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease |
| Q52608828 | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. |
| Q61808996 | Patient-reported severity of dry eye and quality of life in diabetes |
| Q40114745 | Pharmacokinetic-Pharmacodynamic Modeling to Study the Antipyretic Effect of Qingkailing Injection on Pyrexia Model Rats |
| Q37079081 | Pharmacological management of dry eye in the elderly patient |
| Q37826752 | Pharmacotherapy of dry eye. |
| Q91905513 | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease |
| Q36569538 | Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease |
| Q37610134 | Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. |
| Q36168688 | Recent advances in the management of ocular complications of Sjögren's syndrome |
| Q36478996 | Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits |
| Q52661549 | Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. |
| Q34325595 | Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study |
| Q38076070 | Sjögren's syndrome in older patients: aetiology, diagnosis and management |
| Q38171801 | Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. |
| Q35589996 | Systemic cyclosporin A in high failure risk, repeated corneal transplantation |
| Q36864045 | The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study |
| Q36039088 | The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye |
| Q38925320 | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review |
| Q44600963 | The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study |
| Q50480678 | The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome. |
| Q38270449 | The role and treatment of inflammation in dry eye disease |
| Q43171662 | The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model |
| Q34391944 | The treatment of dry eye. |
| Q44498935 | Topical and systemic medications for the treatment of primary Sjögren's syndrome. |
| Q24670344 | Topical ciclosporin in the treatment of ocular surface disorders |
| Q44548621 | Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis |
| Q84735553 | Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients |
| Q90093016 | Topical cyclosporine A therapy for dry eye syndrome |
| Q35087001 | Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury |
| Q36009560 | Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in China |
| Q24188132 | Topical treatments for blepharokeratoconjunctivitis in children |
| Q38760378 | Topical treatments for blepharokeratoconjunctivitis in children. |
| Q36056942 | Treating Sjögren's Syndrome: Insights for the Clinician |
| Q37236096 | Treatment of chronic dry eye: focus on cyclosporine |
| Q30249011 | Treatment of primary Sjögren syndrome |
| Q44203592 | Trehalose eye drops in the treatment of dry eye syndrome |
| Q94466109 | [The dry eye. Current concepts on classification, diagnostics, and pathogenesis] |
Search more.